U.S. Markets open in 9 hrs 23 mins

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
16.37-0.50 (-2.96%)
At close: 4:00PM EDT
People also watch
Full screen
Previous Close16.87
Bid12.23 x 600
Ask17.88 x 300
Day's Range16.30 - 16.91
52 Week Range13.41 - 19.62
Avg. Volume765,634
Market Cap1.72B
PE Ratio (TTM)-12.05
EPS (TTM)-1.36
Earnings DateAug 1, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.60
Trade prices are not sourced from all markets
  • 3 Stocks That Could Be Life-Changers
    Motley Fool3 days ago

    3 Stocks That Could Be Life-Changers

    Above-average risk can lead to above-average rewards if you invest wisely.

  • PR Newswire4 days ago

    Lexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast On August 1, 2017

    THE WOODLANDS, Texas, July 24, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX), will release its second quarter 2017 financial results on Tuesday, August 1, 2017 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EDT (7:00 a.m. CDT) that day to discuss the financial results and to provide a business update.

  • PR Newswire7 days ago

    Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl)

    THE WOODLANDS, Texas, July 21, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX), announced today that the Committee for Medicinal Products for Human Use (CHMP), the committee of the European Medicines Agency (EMA) responsible for human medicines, has adopted a positive opinion for the Marketing Authorization Application (MAA) filed by Lexicon collaborator Ipsen for XERMELO® (telotristat ethyl) 250 mg to treat carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.